跳转至内容
Merck

485A-1

Sigma-Aldrich

ATRX Rabbit Polyclonal Antibody

别名:

ATP-dependent helicase ATRX, X-linked helicase II, X-linked nuclear protein (XNP)

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41116161

生物源

rabbit blood

品質等級

100
500

共軛

unconjugated

抗體表格

IgG fraction of antiserum

抗體產品種類

primary antibodies

描述

For In Vitro Diagnostic Use in Select Regions

形狀

buffered aqueous solution

物種活性

human

包裝

vial of 0.1 mL (concentrate (485A-14))
vial of 0.1 mL (concentrate (485A-14-RUO) Research Use Only)
vial of 0.5 mL (concentrate (485A-15))
vial of 1.0 mL (concentrate (485A-16))
vial of 1.0 mL (concentrate (485A-16-RUO) Research Use Only)
vial of 1.0 mL (concentrate (485A-17-RUO) Research Use Only)
vial of 1.0 mL (pre-dilute ready-to-use (485A-17))
vial of 7.0 mL (concentrate (485A-18-RUO) Research Use Only)
vial of 7.0 mL (pre-dilute ready-to-use (485A-18))

製造商/商標名

Cell Marque

技術

immunocytochemistry: suitable (formalin-fixed, paraffin-embedded sections 1:50-1:50 (concentrated))

同型

IgG

控制

astrocytoma, brain, glioblastoma, oligodendroglioma

運輸包裝

wet ice

儲存溫度

2-8°C

視覺化

nuclear

一般說明

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

品質

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

外觀

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

準備報告

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

其他說明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律資訊

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel J Brat et al.
The New England journal of medicine, 372(26), 2481-2498 (2015-06-11)
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly
Akane Yamamichi et al.
Brain tumor pathology, 35(2), 106-113 (2018-03-20)
The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined.
Matthew D Wood et al.
Diagnostic pathology, 14(1), 29-29 (2019-04-11)
Insights into the molecular underpinnings of primary central nervous system tumors have radically changed the approach to tumor diagnosis and classification. Diagnostic emphasis has shifted from the morphology of a tumor under the microscope to an integrated approach based on
Masako Ikemura et al.
Histopathology, 69(2), 260-267 (2016-01-08)
We performed an immunohistochemical analysis of alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) expression in adult diffuse gliomas, with reference to clinicopathological and genetic features, to determine the utility of this analysis in diagnostic practice. A total of 193 adult diffuse gliomas
David N Louis et al.
Acta neuropathologica, 131(6), 803-820 (2016-05-10)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门